Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 585 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

Liver Disease in Urea Cycle Disorders

NCT04612764
Conditions
Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity, Diabetes, NAFLD, Inflammation
Interventions
Limited dairy diet, Low-fat dairy diet, Full-fat dairy diet
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions
TVB-2640, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
103
States / cities
Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Conditions
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more
Conditions
Healthy, Liver Diseases, Obesity
Interventions
BI 456906
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
Conditions
Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
Interventions
TIPS-obliteration
Device
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
HPN-100, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
90
States / cities
Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
Conditions
Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma, HCC, Hepatitis C, Cirrhosis
Interventions
Embospheres Microspheres
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Conditions
Acute Intermittent Porphyria
Interventions
recombinant human porphobilinogen deaminase (Porphozym)
Drug
Lead sponsor
Zymenex A/S
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Quantification of Liver Iron With MRI

NCT01516853
Conditions
Iron Overload, Hemosiderosis
Interventions
Non-contrast MRI
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Ornithine Transcarbamylase Deficiency, Wilson Disease, Glycogen Storage Disease Type IA
Interventions
Not listed
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions
MN-001
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Coronado, California • La Jolla, California • Seattle, Washington
Conditions
Hypoglycemia
Interventions
Fasting, Feeding
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hepatitis C Infection, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
Pegozafermin, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
150
States / cities
Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
Conditions
Liver Transplant; Complications, NAFLD
Interventions
Saroglitazar
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Suspended No phase listed Observational Accepts healthy volunteers

NAFLD in Adolescents and Young Adults With PCOS

NCT02506946
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
HepQuant
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota